NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis → The 'Smart Money' Is Ready for May 1st Are You? (From Stansberry Research) (Ad) Free NBTX Stock Alerts $5.90 +0.19 (+3.33%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$5.90▼$5.9950-Day Range$5.38▼$7.3852-Week Range$1.75▼$11.00Volume1,366 shsAverage Volume94,039 shsMarket Capitalization$278.07 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Nanobiotix alerts: Email Address Nanobiotix MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside86.4% Upside$11.00 Price TargetShort InterestHealthy0.11% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.90 out of 5 starsMedical Sector578th out of 907 stocksPharmaceutical Preparations Industry262nd out of 422 stocks 3.5 Analyst's Opinion Consensus RatingNanobiotix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNanobiotix has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.11% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 4.14%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBTX. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Nanobiotix this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions. Previous Next N/A Earnings and Valuation Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchThe "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. One Former Wall St. Trader Explains Why… About Nanobiotix Stock (NASDAQ:NBTX)Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Read More NBTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBTX Stock News HeadlinesApril 24, 2024 | globenewswire.comNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial ResultsApril 17, 2024 | globenewswire.comNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024April 25, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.April 2, 2024 | globenewswire.comNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-IrradiationMarch 6, 2024 | globenewswire.comNanobiotix to Present at Upcoming Investor Conferences in MarchJanuary 31, 2024 | finance.yahoo.comNanobiotix to Present at the Guggenheim 6th Annual Biotechnology ConferenceJanuary 30, 2024 | finanznachrichten.deNanobiotix S.A.: Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyJanuary 29, 2024 | finance.yahoo.comNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer StudyApril 25, 2024 | DTI (Ad)A new way to collect income from stocksMost people think of BUYING options when they talk about options. It’s how speculators leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. The problem is - they don’t always pay off when you buy them. In fact, a contributing writer at the Financial Post studied options extensively… January 18, 2024 | seekingalpha.comNBTX Nanobiotix S.A.December 8, 2023 | realmoney.thestreet.comNanobiotix initiated with an Outperform at LeerinkDecember 4, 2023 | finance.yahoo.comNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.November 15, 2023 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 13, 2023 | finance.yahoo.comNANOBIOTIX Provides Third Quarter 2023 Operational and Financial UpdateNovember 9, 2023 | finance.yahoo.comNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023November 9, 2023 | finanznachrichten.deNanobiotix S.A.: Voting Rights and Shares Capital of the CompanyNovember 7, 2023 | finance.yahoo.comNANOBIOTIX Announces Closing of Global OfferingNovember 6, 2023 | finance.yahoo.comNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6MNovember 2, 2023 | msn.comWhy Nanobiotix (NBTX) Stock Is Plunging ThursdayNovember 2, 2023 | finance.yahoo.comNANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55MNovember 2, 2023 | morningstar.comNanobiotix SA ADR NBTXNovember 1, 2023 | finance.yahoo.comNANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash CovenantOctober 23, 2023 | finance.yahoo.comNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023October 5, 2023 | msn.comNanobiotix falls after Phase 1 data for lead asset in head and neck cancerOctober 5, 2023 | markets.businessinsider.comUBS Reaffirms Their Buy Rating on Nanobiotix (NBTX)October 4, 2023 | finance.yahoo.comNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 MonthsSeptember 29, 2023 | finance.yahoo.comNANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation OncologySee More Headlines Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today4/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:NBTX CUSIPN/A CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees101Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+86.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$5.12 million Price / Sales54.31 Cash FlowN/A Price / Cash FlowN/A Book Value($0.82) per share Price / Book-7.20Miscellaneous Outstanding Shares47,130,000Free Float45,507,000Market Cap$278.07 million OptionableNot Optionable Beta0.21 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Laurent Levy Ph.D. (Age 51)Co-Founder, President of the Executive Board & CEO Comp: $674.57kMr. Bart Van Rhijn (Age 51)CFO & Member of Executive Board Comp: $598.42kMs. Anne-Juliette Hermant M.A. (Age 50)Chief People Officer & Member of Executive Board Comp: $328.98kMr. Earl J. Bergey Ph.d. (Age 69)Co-Founder Mr. Alain DostieChief Operating OfficerMr. Craig West CFASenior Vice President of Investor RelationsMr. Brandon OwensVP of Strategic Marketing & Corporate CommunicationMr. Patrick Tricoli M.B.A.Pharm.D., Global Head of Business DevelopmentMs. Margaret GalluzziVP & Global Head of Clinical OperationsMr. Ventzislav Vassilev M.D.VP & Global Head of Safety VigilanceMore ExecutivesKey CompetitorsInozyme PharmaNASDAQ:INZYVanda PharmaceuticalsNASDAQ:VNDAEnanta PharmaceuticalsNASDAQ:ENTARAPT TherapeuticsNASDAQ:RAPTWerewolf TherapeuticsNASDAQ:HOWLView All CompetitorsInstitutional OwnershipBaillie Gifford & Co.Bought 932,835 shares on 1/26/2024Ownership: 6.087%View All Institutional Transactions NBTX Stock Analysis - Frequently Asked Questions Should I buy or sell Nanobiotix stock right now? 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nanobiotix in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NBTX shares. View NBTX analyst ratings or view top-rated stocks. What is Nanobiotix's stock price target for 2024? 2 Wall Street analysts have issued 1-year price targets for Nanobiotix's stock. Their NBTX share price targets range from $11.00 to $11.00. On average, they expect the company's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 86.4% from the stock's current price. View analysts price targets for NBTX or view top-rated stocks among Wall Street analysts. How have NBTX shares performed in 2024? Nanobiotix's stock was trading at $7.28 at the start of the year. Since then, NBTX stock has decreased by 19.0% and is now trading at $5.90. View the best growth stocks for 2024 here. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an IPO on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont acted as the underwriters for the IPO. How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NBTX) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarHe Is Giving Away BitcoinCrypto Swap ProfitsYour Money is Not SafeAmerican AlternativeBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
